title: Drug-related lupus. Incidence, mechanisms and clinical implications.
abstract: Adverse side effects to drugs and chemicals in which immune mechanisms may be responsible have been described in drug-related lupus (DRL). The spectrum of drugs that may elicit DRL includes such classes as the hydrazines, arylamines, and chemicals that can be metabolised to amines. The 2 major pathways of metabolism--acetylation and N-hydroxylation--are described in detail. The events leading to autoantibody production are not well understood; however, specific consideration of the genetic makeup of patients who are candidates for treatment with these drugs may help identify those at risk of developing DRL.
authors.affiliation: Department of Internal Medicine, University of Cincinnati Medical Center, Ohio.
authors.forename: L E
authors.initials: LE
authors.lastname: Adams
authors.forename: E V
authors.initials: EV
authors.lastname: Hess
mesh_terms: D006801:Humans; D008177:Lupus Vulgaris / Q000139:chemically induced*